US EditionMergers and Acquisitions (M&A): CorMedix Inc. (CorMedix) (NASDAQ: CRMD) Acquires Melinta Therapeutics for $300 Million.
Summary by Intelligence360 News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Mergers and Acquisitions (M&A): CorMedix Inc. (CorMedix) (NASDAQ: CRMD) Acquires Melinta Therapeutics for $300 Million.
CorMedix Inc. has announced the acquisition of Melinta Therapeutics. According to the company announcement CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The company is acquiring Melinta Therapeutics, a strategic move that will transform CorMedix into a diversified specialty pharmaceutical organization with a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
